anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Universal screening for Streptococcus agalactiae, Group B Streptococcus (GBS), in pregnant women is important for the prevention of severe infectious diseases in neonates. The subculture method using selective enrichment broth significantly improves GBS detection rates in the United States; however, this method is not widely utilized in Japan mainly because of the lack of large-scale validation. Therefore, we aimed to validate the utility of the subculture method in collaboration with multiple facilities. A total of 1957 vaginal-rectal swab specimens were obtained from pregnant women at 35-37 gestational weeks from March 1, 2020, to August 30, 2020, at Fukushima Medical University Hospital, Aiiku Hospital, Kitano Hospital, and the University of the Ryukyus Hospital. Conventional direct agar plating, subculture using selective enrichment broth, and direct latex agglutination (LA) testing with incubated broth were performed for GBS detection, and discrepant results were confirmed using real-time PCR. The GBS detection rates for direct agar plating, subculture, and direct LA testing were 18.2% (357/1957), 21.6% (423/1957), and 22.3% (437/1957), respectively. The use of selective enrichment broth showed promise for GBS detection with high sensitivity and is therefore recommended for GBS screening to prevent GBS-related infectious diseases in neonates in Japan.
In this study, We aim to explore the association between the neutrophil to lymphocyte ratio (NLR), platelet to lymphocyte ratio (PLR), systemic immune-inflammatory index (SII), lymphocyte to monocyte ratio (LMR) and prognostic nutritional index (PNI) and distant metastasis of gastric cancer and develop an efficient nomogram for screening patients with distant metastasis. A total of 1281 inpatients with gastric cancer were enrolled and divided into the training and validation set.Univariate, Lasso regression and Multivariate Logistic Regression Analysis was used to identify the risk factors of distant metastasis. The independent predictive factors were then enrolled in the nomogram model. The nomogram's predictive perform and clinical practicality was evaluated by receiver operating characteristics (ROC) curves, calibration curves and decision curve analysis. Multivariate Logistic Regression Analysis identified D-dimer, CA199, CA125, NLR and PNI as independent predictive factors. The area under the curve of our nomogram based on these factors was 0.838 in the training cohort and 0.811 in the validation cohort. The calibration plots and decision curves demonstrated the nomogram's good predictive performance and clinical practicality in both training and validation cohort. Therefore,our nomogram could be an important tool for clinicians in screening gastric cancer patients with distant metastasis.
The compounds are applicable in medicine, e.g. for radiotherapy in cancer treatment. They are less toxic and have an optimised sensibilising effect and have the following formula:<IMAGE>where q is 0 or 2. When q is 0, R is OAg and X is 1. When q is 2, R is oxygen and X is 2, n is 1 or 2. According to this method, the respective silver salt of the adenosinemono- or adenosinetriphosphate reacts with 2-deoxycytidine hydrochloride at a 1/1 to 1/3 ratio within a water medium.
Anhedonia, a complex symptom rooted in deficits across reward processes, is primarily linked to depression and schizophrenia but transcends diagnostic boundaries across various mental disorders. Its presence correlates with poorer clinical outcomes, including an increased risk of suicide and diminished response to treatment. The neurobiological underpinnings of anhedonia remain incompletely understood despite advancements in biomarkers and imaging that contribute to deeper insights. Ketamine, known for its rapid-acting antidepressant properties, appears to possess antianhedonic effects through a mechanism of action not fully elucidated. This effect appears to be independent of its antidepressant properties. Explorations into alternative antianhedonic treatments have been underway, yet lingering questions persist, underscoring the imperative need for ongoing research to advance the field.
Review of experience to date suggests that a subgroup of older patients with associated severe illness may tolerate diarrhea less well. When clindamycin is indicated in these patients, they should be carefully monitored for change in bowel frequency.

CLEOCIN HCl should be prescribed with caution in individuals with a history of gastrointestinal disease, particularly colitis.

CLEOCIN HCl should be prescribed with caution in atopic individuals.

Indicated surgical procedures should be performed in conjunction with antibacterial drug therapy.

The use of CLEOCIN HCl occasionally results in overgrowth of nonsusceptible organisms—particularly yeasts. Should superinfections occur, appropriate measures should be taken as indicated by the clinical situation.

Clindamycin dosage modification is not necessary in patients with renal disease. In patients with moderate to severe liver disease, prolongation of clindamycin half-life has been found. However, it was postulated from studies that when given every eight hours, accumulation should rarely occur. Therefore, dosage modification in patients with liver disease may not be necessary. However, periodic liver enzyme determinations should be made when treating patients with severe liver disease.

The 75 mg and 150 mg capsules contain FD&C yellow no. 5 (tartrazine), which may cause allergic-type reactions (including bronchial asthma) in certain susceptible individuals. Although the overall incidence of FD&C yellow no. 5 (tartrazine) sensitivity in the general population is low, it is frequently seen in patients who also have aspirin hypersensitivity.

Prescribing CLEOCIN HCl in the absence of a proven or strongly suspected bacterial infection or a prophylactic indication is unlikely to provide benefit to the patient and increases the risk of the development of drug-resistant bacteria.

Due to the risk of esophagitis and esophageal ulcer, it is important to ensure adherence with administration guidance (See DOSAGE AND ADMINISTRATION and ADVERSE REACTIONS).
COVID-19 is a respiratory disease caused by a novel coronavirus (SARS-CoV-2) that is associated with substantial morbidity and mortality. There is currently no vaccine to prevent COVID-19 or infection with SARS-CoV-2 or therapeutic agent to treat COVID-19.

Many patients with moderate and severe COVID-19, develop a "cytokine storm" that leads to severe pulmonary inflammation and various thrombotic events associated with acute respiratory distress syndrome (ARDS) and potentially death. The combination of masitinib and isoquercetin may prevent the development of these two complications. Masitinib is a potent blocker of mast cells and macrophages that are contributors to the cytokine storm. Isoquercetin inhibits disulfide isomerase (PDI), an enzyme directly involved in the formation of clots, and also decreases D-Dimer, a predictor of COVID-19 thrombosis severity.

The primary objective of this study is to evaluate efficacy of the masitinib and isoquercetin combination in moderate and severe COVID-19 patients. The primary endpoint is subject clinical status at day 15, using a 7-point ordinal scale that is defined as follows: 1. Not hospitalized, no limitations on activities; 2.Not hospitalized, limitation on activities; 3. Hospitalized, not requiring supplemental oxygen; 4. Hospitalized, requiring supplemental oxygen; 5. Hospitalized, on non-invasive ventilation or high flow oxygen devices; 6. Hospitalized, on invasive mechanical ventilation or ECMO; 7. Death.
FIELD: medicine. ^ SUBSTANCE: invention refers to medicine, namely to oncogynaecology, and can be used in treating initial endometrial cancer. The method involves administration of the release gonadotrophin agonist Lucrine-depot (RGn-A) combined with the intrauterine levonorgestrel release system Mirena (LNG-RS). In atypical endometrial hyperplasia (AEH), the RGn-A Lucrine-depot is introduced 3.75 mg 3 times every 28 days; a positive course of the disease requires the administration of the LNG-RS with underlying continuing therapy by the RGn-A 3.75 mg 3 times every 28 days, for the purpose of prevention of the recurrent disease, the LNG-RS is used for at least 6 months. In endometrial cancer (EC), the RGn-A 3.75 mg is introduced. once in 28 days in 3 injections; the positive course of the disease implies the administration of the RGn-A 3.75 mg once in 28 days in 5 injections; the third injection is followed by the administration of the LNG-RS for at least 1 year. ^ EFFECT: use of the invention allows providing higher clinical effectiveness in initial endometrial cancer in women of childbearing age, reducing length of treatment and rehabilitation in the patients, eliminating hormonotherapy associating complications - postinjection abscesses and thrombophlebitises. ^ 2 ex
BACKGROUND AND OBJECTIVES: Little is known about the prevalence of physical pain among family caregivers to older adults. We used national survey data to assess the relative prevalence of caregivers' arthritis and activity-limiting bothersome pain by caregiver and care-recipient characteristics to identify which caregivers may be at a higher risk for physical pain.
RESEARCH DESIGN AND METHODS: We analyzed data collected from 1,930 caregivers who participated in the National Study on Caregiving (2017). We utilized modified Poisson models to estimate adjusted associations of caregiver and care-recipient characteristics with the relative prevalence of arthritis and bothersome pain.
RESULTS: Forty percent of caregivers had a lifetime diagnosis of arthritis. Seventy-five percent of caregivers with arthritis reported bothersome pain, nearly 30% of whom endorsed bothersome pain that limited their activities on most or every day of the previous month (i.e., activity-limiting bothersome pain). Regardless of whether they had arthritis, 51% of the sample reported bothersome pain in the previous month, 24% of whom indicated activity-limiting bothersome pain. Caregivers who were older or more highly educated had a higher prevalence of arthritis. Black caregivers had a lower prevalence of arthritis and activity-limiting bothersome pain compared to White caregivers. Caregivers with physical difficulty providing care had a higher prevalence of arthritis and activity-limiting bothersome pain than caregivers without physical difficulty providing care.
DISCUSSION AND IMPLICATIONS: Arthritis and activity-limiting bothersome pain are highly prevalent among caregivers. Given increased prevalence of pain among certain caregivers, it may be efficient to target these groups for pain management interventions.
OBJECTIVES: I. Determine the safety and the maximum tolerated dose of vaccines containing two adenoviral vectors encoding the melanoma antigens Melan-A/MART-1 and gp100 in patients with stage II-IV melanoma. II. Assess the dose-response changes in the frequency of MART-1 and gp100 reactive T cells (CD4+ and CD8+) in patients receiving one of three different vaccine regimens. III. Assess the T-cell response to one melanoma antigen following three treatments with the other antigen in these patients. IV. Assess the effect of concomitant vaccination with both antigens on T-cell response in these patients.

OUTLINE: This is a dose escalation study. Patients are sequentially enrolled on 1 of 3 treatment arms. Each treatment arm has 3 groups. Arm I: Patients receive Ad2/MART-1v2 vaccine and Ad2/gp100v2 vaccine intradermally (ID) at the lowest dose level once every three weeks for either 6 or 15 weeks depending on assignment. Arm II: Patients receive Ad2/gp100v2 vaccine and Ad2/MART-1v2 vaccine ID at the mid-range dose level once every three weeks for either 6 or 15 weeks depending on assignment. Arm III: Patients receive Ad2/MART-1v2 vaccine and Ad2/gp100v2 vaccine ID at the highest dose level once every three weeks for either 6 or 15 weeks depending on assignment. Cohorts of 3-6 patients receive escalating doses of Ad2/MART-1v2 and/or Ad2/gp100v2 vaccines in each arm until the maximum tolerated dose (MTD) is reached. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. Patients are followed at 3 months, 6 months, and 1 year after completion of treatment.

PROJECTED ACCRUAL: A total of 24-36 patients will be accrued over 1 year.
FIELD: medicine, pharmacology. SUBSTANCE: invention relates to human aging processes. Invention proposes medicinal vegetable agent promoting to prevention of ageing processes and comprising purgative species and rejuvenation species. Purgative species comprises tomentose burdock roots, sickle-shaped alfalfa herb and meadow clover flowers taken in the following ratio of components, wt. -%: tomentose burdock roots, 10.0; sickle-shaped alfalfa herb, 35.0-40.0; meadow clover flowers, 50.0-55.0. Rejuvenation species comprises planted garlic bulbs and fruits of lemon, honeysuckle, bog bilberry, bilberry and common cowberry taken in the following ratio of components, wt. -%: planted garlic bulbs, 20.0-24.0; lemon fruits, 20.0-24.0; honeysuckle fruits, 13.0-15.0; bog bilberry fruits, 13.0-15.0; bilberry fruits, 13.0-15.0; common cowberry fruits, 13.0-15.0. Rejuvenation procedure in the course of treatment improved state of health, night dream of patients, promoted to visible rejuvenation of face skin, decreased the enhanced arterial blood pressure by 10-30 mm of mercury column, relieved migraine-like head pains and enhanced male potency in 100% of cases. EFFECT: enhanced effectiveness of agent, valuable medicinal properties. 1 ex
The present invention relates generally to a mixture of coated and non-coated sulfonic acid cation exchange resins (Amberlite IR69) cross-linked with about 8% divinyl benzene onto which dextromethorphan has been loaded. About 30% of the drug/resin complexes are coated with a mixture of ethyl cellulose or ethyl cellulose latexes with plasticizers and water dispersible polymers such as SURELEASE. The coating level is about 50% w/w drug. Coated and uncoated drug/resin complexes are loaded with drug to about 45% by weight drug/resin complex. The ratio of coated and uncoated drug/resin complexes is about 55/45. The particle sizes of the coated and uncoated drug/resin complexes is about 20 to about 300 and about 20 to about 250 microns, respectively.
The invention is concerned with a kind of medicine compound and its produce method to cure cancer, belonging to medicine technology field. The compound is made of one or some of L- glutamine or its analog, cantharidin and its ramification or its analog, senso, matrine saponin, gynostemma pentaphyllum and marsdenia tenacissima. And it is also made of one or some of L- glutamine or its analog, cantharidin and its ramification or its analog, distilling of senso, matrine saponin, gynostemma pentaphyllum or the distilling of marsdenia tenacissima. They mix with acceptable assistant stuff to make the acceptable products for clinic or medicine. This medicine compound can be used to cure liver cancer, gastric cancer, esophagus carcinoma, colorectal carcinoma, lymphoblastic tumour and malignancy of v reproductive systems with small side effect. It has amazed effect and wide application future.
Novel D 7- and D 1,7-3,6-dioxo-A-nor-B-homo-steroids are prepared by halogenation and basic dehydrohalogenation of rings A and B saturated or D 1 - 3,6 - dioxo - A - nor - B - homo-steroids Enol esters and enol ethers may also be used.  The 5-halo-steroids first formed may be isomerized, or may isomerize spontaneously, to 7-halo-steroids and some 2-halo-steroids which on dehydrohalogenation give D 7- and D 1-compounds respectively.  The latter may then be further halogenated and dehydrohalo-genated to D 1,7-compounds.  The halogenation is effected in an inert organic solvent with a halogen or a hypohalous acid or a compound yielding such.  Resulting hydroxy compounds or their esters or ethers may be converted one into the other and OXO groups may be reduced, with or without concomitant introduction of a hydrocarbon substituent.  The starting materials may belong to the androstane, pregnane, cholane, cholestane, spirostane or cardanolide series or the 19-nor compounds and may contain free, esterified or etherified hydroxyl groups, free or ketalized oxo groups, aliphatic hydrocarbon groups and halogen atoms.  They may also contain one or more additional double bonds.  The compounds of the invention, which may have variously anabolic, gestagenic, ovulation inhibiting, anti-cholesterolaemic, progestational and adrenocortical activity, may be made up into pharmaceutical or veterinary compositions with suitable carriers.
Rationale: Chronic inflammation plays an important role in alveolar tissue damage in emphysema, but the underlying immune alterations and cellular interactions are incompletely understood. Objectives: To explore disease-specific pulmonary immune cell alterations and cellular interactions in emphysema. Methods: We used single-cell mass cytometry (CyTOF) to compare the immune compartment in alveolar tissue from 15 patients with severe emphysema and 5 control subjects. Imaging mass cytometry (IMC) was applied to identify altered cell-cell interactions in alveolar tissue from patients with emphysema (n = 12) compared with control subjects (n = 8). Measurements and Main Results: We observed higher percentages of central memory CD4 T cells in combination with lower proportions of effector memory CD4 T cells in emphysema. In addition, proportions of cytotoxic central memory CD8 T cells and CD127+CD27+CD69- T cells were higher in emphysema, the latter potentially reflecting an influx of circulating lymphocytes into the lungs. Central memory CD8 T cells, isolated from alveolar tissue from patients with emphysema, exhibited an IFN-γ response upon anti-CD3 and anti-CD28 activation. Proportions of CD1c+ dendritic cells, expressing migratory and costimulatory markers, were higher in emphysema. Importantly, IMC enabled us to visualize increased spatial colocalization of CD1c+ dendritic cells and CD8 T cells in emphysema in situ. Conclusions: Using CyTOF, we characterized the alterations of the immune cell signature in alveolar tissue from patients with chronic obstructive pulmonary disease stage III or IV emphysema versus control lung tissue. These data contribute to a better understanding of the pathogenesis of emphysema and highlight the feasibility of interrogating the immune cell signature using CyTOF and IMC in human lung tissue. Clinical trial registered with www.clinicaltrials.gov (NCT04918706).
The present invention relates to a cyclic compound having a 3-dimensional structure which binds to neurotrophin receptors under physiological conditions in vitro or in vivo, and wherein said binding to said receptor at least partially mimics or inhibits said neurotrophin biological activity. The neurotrophin is selected from the group consisting of NGF, BDNF, NT3 and NT-4/5 and the neurotrophin receptor is selected from the group consisting of trkA, TrkB, trkC, trkE and p75. The cyclic compounds of the present invention may be structural analogs of NGF or small monomeric, dimeric or polymeric cyclic compounds that mimic the β-turn regions of NGF. Such structural analogs include at least one 3-D conformation selected from a β-turn at region 28-36 (A'-A'), 43-49 (A'''-B) and 91-98 (C-D) and three consecutive reverse turns at region 59-65 (B-C). The 3-dimensional conformation of these cyclic compounds may be stabilized by oxidation of cysteine residues to disulfide bridge or other means of cyclization. The present invention also relates to the use of the cyclic compound for the in vivo inhibition or mimicry of neurotrophin binding to its receptor, which may inhibit neurite outgrowth in situ and cause treatment of central or peripheral nervous system diseases, tumors and neuromas.
Physical frailty, an age-related decline in the physiological capacity and function of various organs, is associated with higher vulnerability to unfavorable health outcomes. The mechanisms proposed for physical frailty including increased inflammation and oxidative stress are closely related to nutritional status. In addition to traditional nutritional factors such as protein malnutrition and nutrient deficiencies, emerging evidence has focused on the role of functional nutrients including polyphenols, carotenoids, probiotics, prebiotics, omega-3 long-chain polyunsaturated fatty acids (n-3 PUFAs), β-hydroxy-β-methylbutyrate (HMB), coenzyme Q10 (CoQ10), and L-carnitine in modifying the risk of physical frailty syndrome. Although several clinical trials have suggested the beneficial effects of supplementation with polyphenols, HMB, and prebiotics on frailty indices, the current evidence is still not robust to support recommendations on the routine clinical use of such functional nutrients for the management of frailty. Similarly, the association between CoQ10 and frailty was mainly assessed in observational studies, and more randomized controlled trials are needed in this regard. A limited number of studies have reported the beneficial effect of L-carnitine supplementation on frailty indices. Since carnitine is mainly found in skeletal muscle and its measurement is thus challenging due to ethical constraints, it is necessary to examine the effect of different doses of L-carnitine on frailty and its indices in future studies. A large number of interventional studies evaluated the impact of n-3 PUFA supplementation on physical frailty in the elderly and many of them reported improved physical performance following supplementation, especially when combined with resistance training programs. Although promising findings from experimental and observational studies have been reported on functional nutrients, high-quality evidence from randomized controlled trials as well as detailed mechanistic studies are still required to affirm their role in the prevention and/or treatment of physical frailty. This review aims to describe the current state of research on functional nutrients that may modify the development or prognosis of frailty syndrome.
Randomised clinical trial will be held in following the recommendations of the CONSORT (Consolidated Standards of Reporting Trials). Will be recruited participants of both genders, aged between 18 and 60 years, with and without chronic nonspecific low back pain for over 3 months without irradiation for lower limbs. Potential participants with chronic nonspecific low back pain will be referred by their doctors orthopedic surgeons and/or rheumatologists that will make all the assessments and routine exams, for example, Imaging tests, prescription drugs and referral to physical therapy care. The characteristics of participants will be collected through an evaluation form specially designed for this study. This assessment form will contain issues related to demographic and anthropometric data, plus information about the clinical picture of the participants, as for example the use of medications, physical activity level, educational level, prior history of back pain and duration of symptoms.The clinical outcomes will be obtained at the completion of treatment (6 weeks) and at 3, 6, and 12 months after randomization.

The data will be collected by a blinded assessor. The statistical analysis will follow the intention-to-treat principles.
<P>PROBLEM TO BE SOLVED: To provide treatment of reducing obesity.  <P>SOLUTION: Data represent suppression of growth of endometrial tissues implanted into an abdominal cavity by an angiogenesis inhibitor. A dose of TNP-470 used in this pilot trial is one third of an established dose for tumors. The angiogenesis inhibitor is administered to a patient in an effective amount to regulate normal, non-transformed vascularized tissue size and/or growth by regulating its vascular compartment. Examples of tissues that can be controlled include adipose tissue, intestinal polyps, muscle (including cardiac) tissue and endometrial tissue.  <P>COPYRIGHT: (C)2011,JPO&INPIT